《新股表现》药明巨诺(02126.HK)反覆续升近6%创上市新高
上市第四天的药明巨诺(02126.HK)继首挂及上市翌日「潜水」兼曾跌破招股范围(20-23.8元)下限低见19.38元获承接後,股价上市第三天急弹逾19%,今天低开再考验上市价23.8元不破,掉头升破首挂日盘中所创高位25.45元,最高见27.6元上市新高,现造26.5元,续升5.8%,成交已达1,328万股,涉资3.478亿元。
药明巨诺是内地临床及临床前阶段细胞治疗公司,由药明康德(02359.HK)及美国医药研发平台Juno共同投资。是次来港上市共发售9,769.2万股,并已引入10名机构投资者或基金作为基石投资者,合共认购逾4,884万股;公开发售部分获逾448倍超购,认购一手中签率仅5%。上市联席保荐人分别为高盛及瑞银。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.